Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AnGes MG Inks Agreements
June 12, 2006
- Dainippon Sumitomo Announces
June 12, 2006
- Reexamination of Patent for
June 12, 2006
- Japan Should Be "Hub" for Healthcare in Asia: Dr Aoki
June 12, 2006
- AE due to TeGenero's TGN1412
June 12, 2006
- Eliminate Provisional Delivery
June 12, 2006
- Subjects' Protection Key to
June 12, 2006
- Dr Amamoto of NEUES
June 12, 2006
- Central IRBs to Speed Up
June 12, 2006
- BUSINESS NEWS IN BRIEF
June 12, 2006
- JMA to Use Network to Activate
June 12, 2006
- Taiyo Pharm.: Sales Rise 16.6% to \29,191 Mil.
June 12, 2006
- R&D NEWS IN BRIEF
June 12, 2006
- Risk from TGN1412 Could Have Been Predicted: Cambridge Professor
June 5, 2006
- Huntingdon Life Sciences to Expand Japanese Business: Mr Cass
June 5, 2006
- Korosho to Develop Individualized Treatment for Esophageal Cancer
June 5, 2006
- REGULATORY NEWS IN BRIEF
June 5, 2006
- New Requirement Related to IRBs May Delay Clinical Trials: Medical Associations
June 5, 2006
- CMIC Allies with KineMed to Add Value to Aborted Compounds
June 5, 2006
- R&D NEWS IN BRIEF
June 5, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…